Table 1 Baseline characteristics of 272 patients who received combination IFN-α and RBV therapy for HCV
Demographics | |
|---|---|
Mean age (years) | 42 ± 8 |
Males | 150 (55%) |
Caucasians | 204 (75%) |
Asians | 22 (8%) |
Weight (kg) | 79 ± 18 |
HCV Genotype | |
1 | 136 (50%) |
2 | 22 (8%) |
3 | 103 (38%) |
4 | 11 (4%) |
Liver Function Tests (RR) | |
Albumin (36–48 g/L) | 41 ± 2 |
Serum Bilirubin (2–20 μmol/L) | 15 ± 6 |
Alanine Aminotransferase (< 45 U/L) | 133 ± 58 |
γ-Glutamyl Transpeptidase (1–30 U/L) | 98 ± 46 |
Prothrombin time (11–18 seconds) | 15 ± 3 |
Haematological Parameters (RR) | |
Haemoglobin (115–165 g/L) | 142 ± 16 |
White cell counts (4.0–11.0 × 106/mL) | 7.1 ± 2.0 |
Platelets (150–400 × 109/mL) | 168 ± 49 |